Amyotrophic Lateral Sclerosis (ALS) Therapeutics Landscape
The diagnosed ALS prevalent cases in the 7MM (the US, EU5, and Japan) is estimated to be 48,112 in 2020. Over the last decade there has been a substantial increase in the burden of motor neuron disease. Even then, there exists no cure for the disease. The marketed treatment options help control the symptoms and prevent unnecessary complications.
Amyotrophic lateral sclerosis pipeline is quite vast and worldwide some of the key companies such as Cytokinetics, Orphazyme, Orion, Brainstorm Cell Therapeutics, Biogen, AB Science, Ionis Pharmaceuticals, Clene Nanomedicine, Neurosense therapeutics, Amylyx, Immunity harma, MediciNova, Biohaven Pharmaceuticals, and others are involved in developing therapies for ALS.
Some of the key emerging pipeline therapies in the Amyotrophic Lateral Sclerosis (ALS) Treatment Market such as Radicava (Edaravone), Tofersen/ BIIB067, Arimoclomol, Ultomiris (ravulizumab), Verdiperstat and many others have the potential to make an impact on the Amyotrophic lateral sclerosis market size growth in the coming years.
Source: Amyotrophic Lateral Sclerosis (ALS) Therapeutics Landscape